S&P 500   3,811.15 (-0.48%)
DOW   30,932.37 (-1.50%)
QQQ   314.14 (+0.42%)
AAPL   121.26 (+0.22%)
MSFT   232.38 (+1.48%)
FB   257.62 (+1.15%)
GOOGL   2,021.91 (+0.30%)
AMZN   3,092.93 (+1.17%)
TSLA   675.50 (-0.99%)
NVDA   548.58 (+3.06%)
BABA   237.76 (-1.01%)
CGC   32.75 (-1.39%)
GE   12.54 (-1.72%)
MU   91.53 (+3.87%)
NIO   45.78 (-2.20%)
AMD   84.51 (+2.54%)
T   27.89 (-2.58%)
F   11.70 (-0.51%)
ACB   10.52 (-2.77%)
DIS   189.04 (-1.02%)
BA   212.01 (-2.05%)
NFLX   538.85 (-1.44%)
BAC   34.71 (-3.40%)
S&P 500   3,811.15 (-0.48%)
DOW   30,932.37 (-1.50%)
QQQ   314.14 (+0.42%)
AAPL   121.26 (+0.22%)
MSFT   232.38 (+1.48%)
FB   257.62 (+1.15%)
GOOGL   2,021.91 (+0.30%)
AMZN   3,092.93 (+1.17%)
TSLA   675.50 (-0.99%)
NVDA   548.58 (+3.06%)
BABA   237.76 (-1.01%)
CGC   32.75 (-1.39%)
GE   12.54 (-1.72%)
MU   91.53 (+3.87%)
NIO   45.78 (-2.20%)
AMD   84.51 (+2.54%)
T   27.89 (-2.58%)
F   11.70 (-0.51%)
ACB   10.52 (-2.77%)
DIS   189.04 (-1.02%)
BA   212.01 (-2.05%)
NFLX   538.85 (-1.44%)
BAC   34.71 (-3.40%)
S&P 500   3,811.15 (-0.48%)
DOW   30,932.37 (-1.50%)
QQQ   314.14 (+0.42%)
AAPL   121.26 (+0.22%)
MSFT   232.38 (+1.48%)
FB   257.62 (+1.15%)
GOOGL   2,021.91 (+0.30%)
AMZN   3,092.93 (+1.17%)
TSLA   675.50 (-0.99%)
NVDA   548.58 (+3.06%)
BABA   237.76 (-1.01%)
CGC   32.75 (-1.39%)
GE   12.54 (-1.72%)
MU   91.53 (+3.87%)
NIO   45.78 (-2.20%)
AMD   84.51 (+2.54%)
T   27.89 (-2.58%)
F   11.70 (-0.51%)
ACB   10.52 (-2.77%)
DIS   189.04 (-1.02%)
BA   212.01 (-2.05%)
NFLX   538.85 (-1.44%)
BAC   34.71 (-3.40%)
S&P 500   3,811.15 (-0.48%)
DOW   30,932.37 (-1.50%)
QQQ   314.14 (+0.42%)
AAPL   121.26 (+0.22%)
MSFT   232.38 (+1.48%)
FB   257.62 (+1.15%)
GOOGL   2,021.91 (+0.30%)
AMZN   3,092.93 (+1.17%)
TSLA   675.50 (-0.99%)
NVDA   548.58 (+3.06%)
BABA   237.76 (-1.01%)
CGC   32.75 (-1.39%)
GE   12.54 (-1.72%)
MU   91.53 (+3.87%)
NIO   45.78 (-2.20%)
AMD   84.51 (+2.54%)
T   27.89 (-2.58%)
F   11.70 (-0.51%)
ACB   10.52 (-2.77%)
DIS   189.04 (-1.02%)
BA   212.01 (-2.05%)
NFLX   538.85 (-1.44%)
BAC   34.71 (-3.40%)
Log in
NASDAQ:ICLR

ICON Public Competitors

$180.68
-3.76 (-2.04 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$179.54
Now: $180.68
$186.62
50-Day Range
$192.41
MA: $208.90
$220.96
52-Week Range
$104.28
Now: $180.68
$223.62
Volume1.53 million shs
Average Volume383,285 shs
Market Capitalization$9.69 billion
P/E Ratio30.11
Dividend YieldN/A
Beta0.91

Competitors

ICON Public (NASDAQ:ICLR) Vs. IQV, EXAS, INCY, CRL, PPD, and PRAH

Should you be buying ICLR stock or one of its competitors? Companies in the industry of "commercial physical research" are considered alternatives and competitors to ICON Public, including IQVIA (IQV), Exact Sciences (EXAS), Incyte (INCY), Charles River Laboratories International (CRL), PPD (PPD), and PRA Health Sciences (PRAH).

ICON Public (NASDAQ:ICLR) and IQVIA (NYSE:IQV) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability and earnings.

Insider and Institutional Ownership

81.7% of ICON Public shares are held by institutional investors. Comparatively, 87.2% of IQVIA shares are held by institutional investors. 44.0% of ICON Public shares are held by insiders. Comparatively, 6.0% of IQVIA shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares ICON Public and IQVIA's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ICON Public$2.81 billion3.45$373.99 million$6.8826.26
IQVIA$11.09 billion3.33$191 million$5.9432.46

ICON Public has higher earnings, but lower revenue than IQVIA. ICON Public is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

ICON Public has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, IQVIA has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for ICON Public and IQVIA, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ICON Public07502.42
IQVIA021402.88

ICON Public presently has a consensus target price of $194.7273, suggesting a potential upside of 7.77%. IQVIA has a consensus target price of $184.8824, suggesting a potential downside of 4.10%. Given ICON Public's higher possible upside, research analysts plainly believe ICON Public is more favorable than IQVIA.

Profitability

This table compares ICON Public and IQVIA's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ICON Public11.95%21.42%11.85%
IQVIA1.61%18.03%4.64%

Summary

ICON Public beats IQVIA on 8 of the 14 factors compared between the two stocks.

ICON Public (NASDAQ:ICLR) and Exact Sciences (NASDAQ:EXAS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability and earnings.

Insider and Institutional Ownership

81.7% of ICON Public shares are held by institutional investors. Comparatively, 90.4% of Exact Sciences shares are held by institutional investors. 44.0% of ICON Public shares are held by insiders. Comparatively, 1.8% of Exact Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares ICON Public and Exact Sciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ICON Public$2.81 billion3.45$373.99 million$6.8826.26
Exact Sciences$876.29 million26.27$-83,990,000.00($1.49)-91.36

ICON Public has higher revenue and earnings than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than ICON Public, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

ICON Public has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, Exact Sciences has a beta of 1.64, meaning that its stock price is 64% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for ICON Public and Exact Sciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ICON Public07502.42
Exact Sciences031202.80

ICON Public presently has a consensus target price of $194.7273, suggesting a potential upside of 7.77%. Exact Sciences has a consensus target price of $145.3125, suggesting a potential upside of 6.75%. Given ICON Public's higher possible upside, research analysts plainly believe ICON Public is more favorable than Exact Sciences.

Profitability

This table compares ICON Public and Exact Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ICON Public11.95%21.42%11.85%
Exact Sciences-25.27%-11.71%-6.74%

Summary

ICON Public beats Exact Sciences on 9 of the 14 factors compared between the two stocks.

ICON Public (NASDAQ:ICLR) and Incyte (NASDAQ:INCY) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability and earnings.

Insider and Institutional Ownership

81.7% of ICON Public shares are held by institutional investors. Comparatively, 91.4% of Incyte shares are held by institutional investors. 44.0% of ICON Public shares are held by insiders. Comparatively, 16.1% of Incyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares ICON Public and Incyte's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ICON Public$2.81 billion3.45$373.99 million$6.8826.26
Incyte$2.16 billion8.01$446.91 million$2.2335.27

Incyte has lower revenue, but higher earnings than ICON Public. ICON Public is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

ICON Public has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, Incyte has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for ICON Public and Incyte, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ICON Public07502.42
Incyte181102.50

ICON Public presently has a consensus target price of $194.7273, suggesting a potential upside of 7.77%. Incyte has a consensus target price of $102.9333, suggesting a potential upside of 30.86%. Given Incyte's stronger consensus rating and higher possible upside, analysts plainly believe Incyte is more favorable than ICON Public.

Profitability

This table compares ICON Public and Incyte's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ICON Public11.95%21.42%11.85%
Incyte-13.62%-13.66%-9.98%

ICON Public (NASDAQ:ICLR) and Charles River Laboratories International (NYSE:CRL) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability and earnings.

Insider and Institutional Ownership

81.7% of ICON Public shares are held by institutional investors. Comparatively, 92.3% of Charles River Laboratories International shares are held by institutional investors. 44.0% of ICON Public shares are held by insiders. Comparatively, 1.9% of Charles River Laboratories International shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares ICON Public and Charles River Laboratories International's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ICON Public$2.81 billion3.45$373.99 million$6.8826.26
Charles River Laboratories International$2.62 billion5.43$252.02 million$6.7342.52

ICON Public has higher revenue and earnings than Charles River Laboratories International. ICON Public is trading at a lower price-to-earnings ratio than Charles River Laboratories International, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

ICON Public has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, Charles River Laboratories International has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for ICON Public and Charles River Laboratories International, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ICON Public07502.42
Charles River Laboratories International041202.75

ICON Public presently has a consensus target price of $194.7273, suggesting a potential upside of 7.77%. Charles River Laboratories International has a consensus target price of $241.5625, suggesting a potential downside of 15.58%. Given ICON Public's higher possible upside, research analysts plainly believe ICON Public is more favorable than Charles River Laboratories International.

Profitability

This table compares ICON Public and Charles River Laboratories International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ICON Public11.95%21.42%11.85%
Charles River Laboratories International10.68%22.41%7.66%

ICON Public (NASDAQ:ICLR) and PPD (NASDAQ:PPD) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability and earnings.

Profitability

This table compares ICON Public and PPD's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ICON Public11.95%21.42%11.85%
PPD0.21%-11.06%2.75%

Analyst Ratings

This is a summary of recent ratings and price targets for ICON Public and PPD, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ICON Public07502.42
PPD001603.00

ICON Public presently has a consensus target price of $194.7273, suggesting a potential upside of 7.77%. PPD has a consensus target price of $35.20, suggesting a potential upside of 0.40%. Given ICON Public's higher possible upside, research analysts plainly believe ICON Public is more favorable than PPD.

Insider and Institutional Ownership

81.7% of ICON Public shares are held by institutional investors. Comparatively, 68.8% of PPD shares are held by institutional investors. 44.0% of ICON Public shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares ICON Public and PPD's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ICON Public$2.81 billion3.45$373.99 million$6.8826.26
PPD$4.03 billion3.04$47.82 million$0.9835.78

ICON Public has higher earnings, but lower revenue than PPD. ICON Public is trading at a lower price-to-earnings ratio than PPD, indicating that it is currently the more affordable of the two stocks.

Summary

ICON Public beats PPD on 9 of the 13 factors compared between the two stocks.

PRA Health Sciences (NASDAQ:PRAH) and ICON Public (NASDAQ:ICLR) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability and risk.

Profitability

This table compares PRA Health Sciences and ICON Public's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PRA Health Sciences7.09%22.21%7.04%
ICON Public11.95%21.42%11.85%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for PRA Health Sciences and ICON Public, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PRA Health Sciences16402.27
ICON Public07502.42

PRA Health Sciences presently has a consensus target price of $110.20, suggesting a potential downside of 25.24%. ICON Public has a consensus target price of $194.7273, suggesting a potential upside of 7.77%. Given ICON Public's stronger consensus rating and higher possible upside, analysts clearly believe ICON Public is more favorable than PRA Health Sciences.

Insider & Institutional Ownership

96.1% of PRA Health Sciences shares are owned by institutional investors. Comparatively, 81.7% of ICON Public shares are owned by institutional investors. 1.3% of PRA Health Sciences shares are owned by insiders. Comparatively, 44.0% of ICON Public shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

PRA Health Sciences has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Comparatively, ICON Public has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500.

Valuation and Earnings

This table compares PRA Health Sciences and ICON Public's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PRA Health Sciences$3.07 billion3.08$243.02 million$4.8030.71
ICON Public$2.81 billion3.45$373.99 million$6.8826.26

ICON Public has lower revenue, but higher earnings than PRA Health Sciences. ICON Public is trading at a lower price-to-earnings ratio than PRA Health Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

ICON Public beats PRA Health Sciences on 9 of the 14 factors compared between the two stocks.


ICON Public Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
IQVIA logo
IQV
IQVIA
2.1$192.79-0.1%$36.88 billion$11.09 billion211.86
Exact Sciences logo
EXAS
Exact Sciences
1.6$136.12-3.5%$23.02 billion$876.29 million-61.59Analyst Downgrade
Insider Selling
News Coverage
Incyte logo
INCY
Incyte
1.9$78.66-0.3%$17.29 billion$2.16 billion-50.10Insider Buying
Charles River Laboratories International logo
CRL
Charles River Laboratories International
1.5$286.14-2.1%$14.24 billion$2.62 billion47.69Analyst Upgrade
Insider Selling
PPD
PPD
1.7$35.06-0.5%$12.26 billion$4.03 billion233.73Earnings Announcement
Analyst Report
Analyst Revision
PRA Health Sciences logo
PRAH
PRA Health Sciences
1.5$147.41-1.2%$9.46 billion$3.07 billion43.10Earnings Announcement
Analyst Downgrade
High Trading Volume
News Coverage
Syneos Health logo
SYNH
Syneos Health
1.6$77.35-1.2%$8.07 billion$4.68 billion42.50Unusual Options Activity
Exelixis logo
EXEL
Exelixis
1.9$21.66-1.4%$6.76 billion$967.78 million45.13Insider Selling
Medpace logo
MEDP
Medpace
1.2$162.43-2.1%$5.80 billion$860.97 million49.67Analyst Downgrade
Precigen logo
PGEN
Precigen
1.7$8.44-1.8%$1.57 billion$90.72 million-4.49Upcoming Earnings
Analyst Report
News Coverage
NRC
National Research
0.6$51.67-3.4%$1.31 billion$127.98 million35.15
Anavex Life Sciences logo
AVXL
Anavex Life Sciences
1.5$13.02-0.3%$904.73 millionN/A-28.93Analyst Report
Analyst Revision
Luna Innovations logo
LUNA
Luna Innovations
1.0$11.74-1.7%$362.04 million$70.52 million65.22
BASI
Bioanalytical Systems
1.1$17.04-9.6%$189.67 million$60.47 million-40.57Analyst Upgrade
Gap Down
ELOX
Eloxx Pharmaceuticals
1.3$4.51-12.4%$181.09 millionN/A-4.51Upcoming Earnings
High Trading Volume
Pieris Pharmaceuticals logo
PIRS
Pieris Pharmaceuticals
1.4$2.72-2.9%$152.24 million$46.28 million-5.13
Cleveland BioLabs logo
CBLI
Cleveland BioLabs
0.6$5.79-7.4%$77.45 million$1.11 million0.00
AIKI
AIkido Pharma
0.6$1.19-3.4%$41.56 million$10,000.000.00
TENX
Tenax Therapeutics
1.4$2.15-3.7%$27.13 millionN/A-1.78
This page was last updated on 2/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.